Nash D T
G Ital Cardiol. 1976;6(3):550-5.
A new cholesterolol lowering agent, DH581, has been studied in eighteen patients with elevated cholesterol levels for more than one year. The data showed twelve patients studied as being cholesterol responders with an overall decrease of 21%. The Placebo period had an overall rise in cholester with a return of effect after re-administration of the drug. During the remainder of the study period, responders had a 17% decrease in cholesterol. Non-responders varied widely but did not demonstrate a significant cholesterol decrease. Triglyceride levels demonstrated wide fluctuation. Nine responders of eighteen patients studied had an overall decrease of 32% and the remainder demonstrated an increase in triglyceride values. Weight changes were not significant and did not account for the observed changes. There was no consistent relationship of sex to the observed response. DH581 appears to be effective antyhypercholesterolemic drug of low toxicity.
一种新型降胆固醇药物DH581，已在18名胆固醇水平升高的患者中进行了为期一年多的研究。数据显示，12名接受研究的患者为胆固醇反应者，胆固醇总体下降了21%。安慰剂阶段胆固醇总体上升，重新给药后药效恢复。在研究期的剩余时间里，反应者的胆固醇下降了17%。无反应者差异很大，但胆固醇没有显著下降。甘油三酯水平波动很大。在接受研究的18名患者中，9名反应者的甘油三酯总体下降了32%，其余患者的甘油三酯值有所上升。体重变化不显著，也无法解释观察到的变化。性别与观察到的反应之间没有一致的关系。DH581似乎是一种低毒性的有效抗高胆固醇血症药物。
